Basic HTML Version
101
SCIENTIFIC REPORT 2012
Title:
Epidemiological, retrospective and cross - sectional study: study on the screening of
hepatitis B virus infection -HBV- in patients with rheumatic diseases
they will receive immunosuppressive treatment.
District Attorney:
Health Park.
Principal Investigator:
Blai Dalmau Obrador.
Title:
Phase III, randomized, double-blind, placebo-controlled study to evaluate the
safety and efficacy of ART-123 in patients with severe sepsis and coagulopathy.
District Attorney:
Ashai Kasei Pharma America Corporation.
Principal Investigator:
Antoni Artigas Raventós.
Title:
Phase III study, comparative, randomized, multicenter, double-blind, with double
simulation of parallel groups to determine the efficacy, safety, tolerability of
ceftazidime avibactam (CAZ-AVI, formerly CAZ104) versus doripenem, followed by
appropriate oral treatment, in the treatment of compiled urinary tract infections, including
acute pyelonephritis, caused by a gram-negative pathogen in hospitalized adults.
District Attorney:
Astrazeneca AB.
Principal Investigator:
Antoni Artigas Raventós.
Title:
oXiris treatment in patients with septic shock: The ECRO study (Endotoxin and Cytokines
Removal with oXiris treatment.
District Attorney:
GAMBRO
Principal Investigator:
Antoni Artigas Raventós.
Title:
Open phase III study to evaluate the efficacy and continuity of treatment with
boceprevir in patients co-infected with HIV and HCV (genotype 1) who have failed to
previous treatment with peginterferon and ribarvirin.
District Attorney:
Clinical Foundation for Biomedical Research.
Principal Investigator:
A hard tackle from Manel Cervantes to García.
Title:
Phase III study, multicenter, double-blind, randomized, to compare efficacy and
safety of intravenous CXA-201 with that of meropenem in intra-abdominal infections
complicated.
District Attorney:
Cubist Pharmaceuticals, Inc.
Principal Investigator:
Ignacio Martín-Loeches Carrondo.